Moderna, Inc., a clinical sta$✔₩ge biotechnology company pione★±ering messenger RNA (m •™RNA) therapeutics and vaccines to create a nπ‍φλew generation of transformative mediciβ  nes for patients, today announ¶λced that the U.S. Food and Drug Admi₩λβ↕nistration (FDA) has grante≥★d Fast Track designation for its investigatio ₹nal Zika vaccine (mRNA-1893) currently being evβε aluated in a Phase 1 study for thΩφ↑e prevention of Zika virus infection in he↕λ"↑althy adults.Fast TraΩ™ck is designed to facilitate the development a¶±nd expedite the review of therapie∑↑​s and vaccines for serious con↕₩ditions and fill an unmet mπ≤∑✘edical need. Programs with Fast Track des↕©εignation may benefit &×♦★from early and frequent communication with th ©≠e FDA, in addition to a rolling submissio‌‌n of the marketing application. Moderna prδ∏÷→eviously received Fas₽♥ t Track designation for£§γ its methylmalonic acidem₩₹ia (MMA) program (mRNA-3704), which is®↓£ now recruiting patients for a Phas×‌εe 1/2 clinical study.“ ‍™Protecting against Zika virus transmission, ©→§particularly in women during pregnancy, continues∏≠γ to be an area of high unmet need. Fast Tra ©£ck designation supports our ✔★↕belief in the clinical potent® ♣ ial of mRNA-1893 and the importance o↓✔f developing an effective vaccine that ca  €©n be rapidly developed ₹  and deployed,” said Tal Zaks, M.D., Ph.D., c★∏§hief medical officer at Mo♠≠×derna. “Our Zika program is part of Mod∏σerna’s broader commit✔↔♠ment to improving global public♠← health through devel¶♥ε​oping mRNA vaccines to pr↑≤event the spread of infectious di§ ↓seases.”mRNA-1893 contains an mRNA sequence   ¶±encoding for the stru→₽‌ctural proteins of Zika virus and is π‌designed to cause cells to secrete virus-like par★<ticles, mimicking the response of the cell aft♥ ∏↔er natural infection. Precli<λnical data published in ✘€ The Journal of Infectious Diseases have shown§♦ε• that vaccination with mRNA-1893 protected agains≥∞t transmission of Zika virus durin♥₹€≥g pregnancy in mice.1 mRNA-1893 ™€♣is currently in a Phase 1 study evaluating s↔∞✘§afety, pharmacokinet≠"₽ ics and pharmacodynamics in healthy volunteers.Th€φ<™is project has been funded in whole or in par₹×↕®t with Federal funds from the Department of Healt★αh and Human Services (HHS);σε♦‍ Office of the Assis÷±tant Secretary for Preparedness and Response; ♦≤Biomedical Advanced R"×♦esearch and Development Authoritα₩₽‍y (BARDA), under Contract No. HHS₹"∑O100201600029C.from--Pharma Focu $∞s AsiaIn recent years, the size of th↑​e global pharmaceutical market has mainta™£∏ ined a steady growth, with China, South Kore✔₹•>a, India and other emerging markets ≠αpresenting a rapid growth momentum.&₩≈nbsp;Due to the different intellectu↑§✘Ωal property policies of diffe↔♥‌‍rent countries, the strategic la‍≤yout of global intellectual property, the diffσ•÷erences of pharmaceutical intellectu&✘≥>al property policies of Asia←&÷φ-pacific countries, the &​♥÷patent review process, litigation procedu& ★©res and Generic drug patent strategy have gradu¥<♣ally become the hot spots of the pharmaceuti≠ cal intellectual pro♦↑perty industry. In thiσ>>s context, the 2019 Aφ±‍≠sia-pacific Pharmaceutical ★✔IP Leader Summit will b×$e held in Beijing on November 14-15, and wil♦☆↕ l attract more than 500 industry experts froλ♥←™m domestic and foreign pharmaceutical co↑αmpanies, biotechnology ✘♥¶♠companies, governments, ass€Ωεociations, law firms, intellectual proper¥₹♣∑ty agents and other companies to attend.β‍2019 Asia-pacific pharma IP Leadeλ r Summit Official regisΩφtration and consultation → δ channels:Contact：AnnPhone≠¶Ω: 021-65650305Email：Marketing@zenseegro∏σ≠up.com